Table.
Literature Review of Cases with Positive Anti-striated Antibody Related to Immune-related Adverse Events of ICIs.
| Case | (Reference) | Age | Sex | Initial presentation | Type of cancer | Type of ICI | Cycles of ICIs | Anti-AChR antibody | Type of anti-striated antibody | Thymoma | Peak CK (U/L) | Myositis | Myasthenia-like syndrome | Myocarditis | Treatment | Outcome |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | (7) | 73 | M | Lower back pain, profound weakness, ptosis, and extraocular muscle weakness | Transitional cell cancer of the renal pelvis | Ipilimumab/ Nivolumab |
2 | No | ND | ND | 13,710 | Yes | Yes | No | Steroid pulse, IVIG, PSL, plasmapheresis, infliximab | Died at 4 months |
| 2 | (8) | 49 | F | Nausea | Melanoma | Ipilimumab/ Nivolumab |
1 | ND | ND | ND | 335 | No | No | Yes | PSL, IVIG | Alive at 275 days |
| 3 | (9) | 87 | M | Double vision, ptosis, muscle weakness, and nasal voice | Urothelial cancer | Atezolizumab | 2 | Yes | ND | No | 1,542 | Yes | Yes | Yes | PSL, IVIG, pyridostigmine | Died at 3 days |
| 4 | (10) | 78 | M | Dyspnea and mild weakness of the neck and upper limbs | Bladder cancer | Pembrolizumab | 1 | Yes | Aanti-titin and anti-Kv1.4 | No | 2,015 | Yes | Yes | No | Steroid pulse, PSL, IVIG | Alive at 5 months |
| 5 | (11) | 78 | F | Diplopia, muscle weakness, and myalgias | Melanoma | Ipilimumab/ Nivolumab |
1 | ND | ND | ND | 9,198 | Yes | Yes | Yes | Steroid pulse, IVIG, plasmapheresis | ND in detail (palliative care) |
| 6 | (12) | 76 | F | General fatigue | Urothelial cancer | Pembrolizumab | 3 | No | Anti-titin | No | 3,527 | Yes | Yes | Yes | PSL, IVIG | Alive at 3 months |
| 7 | (13) | 73 | M | Diplopia | Lung adenocarcinoma | Pembrolizumab | 1 | No | Anti-titin | ND | 7,311 | Yes | Yes | No | Steroid pulse, PSL | Alive at 4 months |
| 8 | (14) | 86 | M | Decreased vision, fatigue, and lower back and bilateral hip pain | Cutaneous squamous cell carcinoma | Cemiplimab | 1 | Yes | ND | ND | 6,407 | Yes | Yes | Yes | Steroid pulse, IVIG, plasmapheresis | Dead |
| 9 | (15) | 75 | M | Generalized muscle weakness, shortness of breath, double vision and ptosis | Malignant mesothelioma | Pembrolizumab | 2 | No | Anti-titin | ND | 3,480 | Yes | Yes | Yes | PSL, plasmapheresis | Alive at 1 year |
| 10 | (Our case) | 77 | F | Myalgia, ophthalmoplegia, and ptosis | Non-small cell lung cancer | Nivolumab | 2 | No | Aanti-titin and anti-Kv1.4 | No | 11,297 | Yes | Yes | Yes | Steroid pulse, PSL, IVIG | Dead at 29 days |
AChR: acetylcholine receptor, CK: creatine kinase, F: female, ICI: immune checkpoint inhibitor, IVIG: intravenous injection of immunoglobulin, M: male, ND: not described, PSL: prednisolone